M&A Analysis 2018
M&A Analysis 2018
$3,000.00
PharmaVitae has launched the M&A Outlook 2018 report, click to view the 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
Publisher: Datamonitor Healthcare
- Description
- Contents
PharmaVitae has launched the M&A Outlook 2018 report, click to view the 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
ABOUT THIS REPORT
PharmaVitae explores the rationale for accelerated dealmaking in 2018, earmarking companies touted for M&A activity, and details 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys.
KEY QUESTIONS ANSWERED
Explore and visualize deal dynamics in the PharmaVitae portfolio up to Q1 2018.
- How are biopharmaceutical companies using M&A as a vehicle to propel a strategy for growth?
- Deal drivers | What are the main drivers for accelerated dealmaking in 2018?
- Deal types | What types of deals can biopharmaceutical companies make?
- 2018 deals | What are the most prominent deals in 2018 so far?
- Potential acquirers | What companies are out on the prowl for M&A deals?
- Takeover targets | What companies constitute the most likely targets across a range of value buckets?
HIGHLIGHTS
- Traction | PharmaVitae expects M&A traction to further accelerate in 2018 on the back of clarifying uncertainties including tax
reform and pricing legislation. - Tax | The ability to repatriate ex-US cash at a one-time tax rate of 10% and lower corporate tax will allow biopharma to allocate
capital towards higher-risk dealmaking. - Targets | Companies will continue to use disciplined M&A as a vehicle to sharpen strategic focus into therapeutic areas that
have critical mass, paving the way for a few larger deals.
ABOUT THE DATA
- Deal information is sourced from Medtrack up to Q1 2018.
- Deals by segment refer to the type of company being acquired, irrespective of the industry of the acquirer.
CONTENTS
5 OVERVIEW
5 About this Report
6 EXECUTIVE SUMMARY
7 DEAL DRIVERS AND OPPORTUNITIES
7 Deal drivers
10 Deal types
15 2018 DEALS
15 What’s going on so far?
15 Sanofi plunges into rare blood disorders with its recent acquisitions
18 $9bn Juno acquisition to propel Celgene to cellular immunotherapy leadership
21 Roche’s acquisition of Flatiron leads Big Pharma in exploiting Big Data
23 POTENTIAL ACQUIRERS
23 Amgen
23 Gilead
23 Novo Nordisk
24 Pfizer
25 TAKEOVER TARGETS
25 $0-2bn
29 $2-10bn
32 $10bn+
37 BIBLIOGRAPHY
LIST OF FIGURES
8 Figure 1: Big Pharma year-on-year growth, 2007–21
9 Figure 2: 2008, 2012, and 2016 M&A cycles by year and quarter – pharmaceutical and biotechnology deals
10 Figure 3: Value of cash and cash equivalents, by company
11 Figure 4: Targeted dealmaking ($1–10bn), 2000–18
14 Figure 5: 2008, 2012, and 2016 cycle comparison
LIST OF TABLES
25 Table 1: Takeover targets bracketed by market capitalization ($bn) on 30 March 2018
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Spinal Cord Stimulation Devices Market 
Sign up to the